Catalyst Pharmaceuticals

Yahoo Finance • 14 days ago

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 19 days ago

Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a consensus Buy with all seven analysts covering it assigning it... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 2 months ago

Catalyst raises 2025 revenue guidance to $565M–$585M while launching $200M share buyback program

Earnings Call Insights: Catalyst Pharmaceuticals (CPRX) Q3 2025 MANAGEMENT VIEW * Richard John Daly, President and CEO, stated that "Catalyst delivered outstanding third quarter 2025 results with accelerating momentum, strong demand fo... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of $148.4Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Mi... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for pe... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel med... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals

The practice of value investing centers on identifying companies trading below their intrinsic worth, a strategy pioneered by Benjamin Graham and later refined by investors like Warren Buffett. This approach emphasizes purchasing securitie... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a noteworthy candidate for investors using a Growth At Reasonable Price (GARP) strategy, which looks for companies showing strong growt... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a notable candidate via the Caviar Cruise stock screening method, a systematic process made to find high-quality companies suitable for... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 4 months ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals settles lawsuit with Lupin

[law legal] utah778/iStock via Getty Images Catalyst Pharmaceuticals (NASDAQ:CPRX [https://seekingalpha.com/symbol/CPRX]) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an en... Full story

Yahoo Finance • 4 months ago

Catalyst settles patent dispute with Lupin over FIRDAPSE

CORAL GABLES, Fla. - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a $2.58 billion market cap biopharmaceutical company with an impressive 83% gross profit margin, announced Monday it has reached a settlement agreement with Lupin Ltd and L... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story